Entering text into the input field will update the search result below

Relmada (RLMD) rockets 55% after REL-1017 indicates lack of abuse potential in major depressive disorder study

  • Relmada Therapeutics (NASDAQ:RLMD) soars 55% premarket after announcing top-line results of the human abuse potential (HAP) study with REL-1017, the company's lead candidate in Phase 3 development for the treatment major depressive disorder (MDD).
  • Top-line results showed that all three doses of REL-1017 (25 mg, 75 mg

Recommended For You

About RLMD Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RLMD--
Relmada Therapeutics, Inc.